Suven Life Sciences Limited · NSE:SUVEN
Suven Life Sciences — Investor Presentation (March 2016)
37 slides from Suven Life Sciences's investor presentation, March 2016
Slide 1: Corporate Presentation
‘Suven Life Sciences Limited Corporate Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accur
Slide 3: Table of Contents
Table of Contents 1 Company Overview 2 Our Business Strategy 3 Our Financial Approach In search of new CNS therapies for better living 3
Slide 4: Company Overview
© | Company Overview
Slide 5: Business Model
Business Model Lead NCE based Formulation Clinical Supplies Chem lib/ comb identification / Lead Process Development & Pre - Clinical intermediates/ Manufacturing & chem hits characterization Optimisation Research Analytical APIs Packaging Services Contract Discovery Research And Research Manufactur
Slide 6: Mission
Mission Providing world-class R&D solutions for Global Life Science companies with quality, speed and in a cost effective manner In search of new CNS therapies for better living In search of new CNS therapies for better living 6
Slide 7: Our Evolution
Our Evolution Diverse and entrenched business Pioneer in CRAMS relationships Well integrated CRAMS and Proven ability and expertise Discovery services 1992 2003 2006 Complex In-house Initiation of CNS chemicals Drug programs with Discovery SUVN-502 as lead molecule 1989 1995 2005 2015 Generi
Slide 8: Company Overview
Company Overview Profitable and dividend paying since listing in 1995 on the NSE and BSE Established Contract Research And Manufacturing Services (CRAMS) - Leader and innovator for NCE based intermediates FY15 Revenue INR 529 Cr 114+3 Number of active CRAMS projects World class infrastructur
Slide 9: Suven Discovery
Suven Discovery SUVN 502 ongoing Phase 2a (POC) clinical trial in USA; expected data read-out in Q4-2017; Enrollment of 537 patients in USA for Alzheimer’s disease SUVN-G3031 for Cognition in Alzheimer’s Disease completed Phase 1 Clinical Trial in USA under US-IND and undergoing long term toxico
Slide 10: Our Focus
Our Focus A full fledged bio-pharmaceutical solutions provider for global pharmaceutical companies 1 Focused on value addition in research and development 2 Investing in R&D over a decade specializing in CNS segment 3 NCE based CRAMS In search of new CNS therapies for better living 10
Slide 11: Business Drivers
Business Drivers Promising NCE Pipeline Industry relationships Execution Capabilities Strong Research Orientation Focus on driving quality research projects for clients In search of new CNS therapies for better living 11
Slide 12: Business Drivers
Business Drivers Promising NCE An integrated research service Pipeline provider with unmatched capabilities Well qualified research team of Industry 386 scientists of which 30 are PhD relationships holders Undertaken 700+ CRAMS projects since inception Execution Pioneer in CRAMS business – C
Slide 13: Key Differentiators
Key Differentiators Suven Others Contract research Contract manufacturing Innovation led Process led Pioneer in CRAMS Followers & ‘Me-too’ segments Long term approach Short term approach High focus on NCEs Mostly generics Full spectrum services Mostly chemistry services In se
Slide 14: Business Drivers
Business Drivers Promising NCE Pipeline Present across the entire CRAMS value chain – intermediates & APIs Industry Leveraging on research relationships capabilities to delivering NCE research State of the art facilities located Execution across Capabilities Strong Research Orientation In sear
Slide 15: Multi Location Facilities
Multi Location Facilities 300 CM reactors (93) 500L to 10 KL GL/SS GMP Intermediates Pashamylaram, Andhra Suryapet, Andhra Vizag, Andhra Pradesh, India Banjara Pradesh, India Pradesh, India SUVEN API & Hills, Hyderabad, India SUVEN Intermediate Mfg. Formulation Facility Corporate Office Facili
Slide 16: Business Drivers
Business Drivers Promising NCE Repeat business owing to long standing relationships with MNC Pipeline companies Long term commercial supply opportunity with the launch of Industry product by global sponsors relationships Working with innovator companies in developed markets having stringent re
Slide 17: Our Relationships
Our Relationships In search of new CNS therapies for better living 17
Slide 18: CRAMS Growth
CRAMS Growth Rs/crores 600 529 513 500 400 300 259 206 200 147 151 123 130 113 90 100 66 53 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 In search of new CNS therapies for better living 18
Slide 19: Business Drivers
Business Drivers Promising NCE One of the few players in the world in the high value CNS segment Pipeline research Built strong intellectual capabilities in CNS segment since 2005. Industry relationships Globally CNS is the second largest and fastest growing segment A single successful molec
Slide 20: Suven Management Team
Suven Management Team Dr. Ramakrishna Nirogi VP Discovery Research Dr. Veera Reddy Arava VP Process Research Dr. Rajendiran Chinnapillay VP Process Research Dr. Padmakumar Kaimal VP Strategic Affairs Mr. Venkat Jasti Mr. Murthy VSN VP Technical Chairman & CEO Mr. Mohan Rao Mannem VP Business Develop
Slide 21: Our Business Strategy
Our @ 4 f Business : Strategy
Slide 22: The CRAMS Value Chain
The CRAMS Value Chain Suven’s position NCEs High margin Segment Under patent molecule Pre-generics (PARA IV) Medium margin Specialized generics, Specialty chemicals Low Low end margin generics, Older molecules, Fine chemicals In search of new CNS therapies for better living 22
Slide 23: Suven Revenue Profile
Suven Revenue Profile Sales growth with strong customer relationship Multi-year NCE based contract research for chemistry development for global sponsors. Long term commercial supply opportunities Pipeline of 61 Phase 1, 52 phase 2, 1 phase 3 projects and 3 commercial stage 23 In search of n
Slide 24: Suven Market Opportunity
Suven Market Opportunity Customer focused long standing relationships for various early phase to commercial chemistry development Geographically dispersed in global markets (USA, Europe, Japan, Korea, Israel) Niche products DMFs and ANDAs for regulated markets Growing opportunity for contrac
Slide 25: Key Risks and Challenges
Key Risks and Challenges Sustaining long term relationships with innovator companies Potential price fluctuation/attrition Likely increase in competition from other Indian/global players Lack of disclosure due to CDAs Potential for lumpiness in revenues and profits 25 In search of new CNS
Slide 26: Key Takeaways
Key Takeaways Growth in CRAMS to fund drug discovery An integrated solutions provider for CNS in Asia. In-house drug discovery programs with future out- licensing opportunities In search of new CNS therapies for better living 26
Slide 27: Drug Discovery R&D - CNS
Drug Discovery R&D - CNS Why CNS? Central Nervous System (CNS) market is the Second Largest Therapeutic Category (15%) and it is one of the Fastest Growing segment Highly unmet medical need More than 200 compounds under development Challenges – High attrition during discovery and clinical
Slide 28: Potential First-in-Class medicines in selected therapeutic areas in United States
Potential First-in-Class medicines in selected therapeutic areas in United States CNS holding highest position 90% 84% 81% 80% 79% 80% 72% 71% 69% 70% 60% 57% 50% 40% 30% 20% 10% 0% Neurology Cadiovascular Cancer Psychiatry Immunology Diabetes HIV/AIDS Infections Source: PhRMA 2015 report and articl
Slide 29: Quick overview of Alzheimer's disease
Quick overview of Alzheimer’s disease An estimated 5.3 Million Americans of all ages have Alzheimer's disease in 2015 and estimated 5.1 Million are age 65 and older. Alzheimer’s disease is the 6th leading cause of death in the United States It is the only cause of death in the top 10 in Americ
Slide 30: Population with Alzheimer's disease
Population with Alzheimer’s disease Women constitute two-thirds of 5.3 Million Americans with Alzheimer's Americans with Alzheimer’s disease aged disease in 2015 65 and above Age > 65, 5.1 Women, 3.2 Million, 96% Million, 63% Age < 65, 0.2 Million, 4% Men, 1.9 Million, 37% Globally 26 Million people
Slide 31: Suven NCE Assets in CNS
Suven NCE Assets in CNS Pre-clinical & Clinical Phase Candidates Indication GLP Tox I II III SUVN-502 5-HT6 antagonist Cognitive Deficits SUVN-G3031 Associated with H3 inverse agonist Alzheimer's Disease SUVN-D4010 5-HT4 agonist SUVN-911 Depression α4β2 antagonist (MDD) Potential to address the unme
Slide 32: Exit Potential For SUVN-502 – Similar compounds
Exit Potential For SUVN-502 – Similar compounds Lu AE58054 (Lundbeck, Otsuka) July 2013 $150 Mn upfront for phase II program. Ongoing phase III RVT-101 (GSK, Axovant) December 2014 Bought post POC compound in Dec 2014 from GSK for $5 Mn + future milestones worth $160 Mn and sales royalties. Raised $
Slide 33: Our Financial Approach
Our @ 4 f Financial : Approach
Slide 34: Financial Approach
Financial Approach R&D cost expensed out each year Prudent utilization of cash flows Low debt Shareholder value creation focus Consistently dividend paying In search of new CNS therapies for better living 34
Slide 35: Key Ratios FY15
Key Ratios FY15 PAT to Income 21% EBIDTA to Income 32% Cash Flow to Income 23% Pre - R&D EBITDA to Income 42% In search of new CNS therapies for better living 35
Slide 36: Financial Table – FY2015
Financial Table – FY2015 YoY Year ending Mar 31, 2015 FY15 FY14 Growth ` % of ` % of % Million Turnover Million Turnover Income 5,294.36 - 5,133.42 - 3.14 Pre-R&D EBITDA 2,240.02 42.31 2,700.36 52.60 (17.05) Pre-R&D EBITDA Margin 42.31% 0.00% 52.60% 0.00% 0.00% EBITDA 1,680.40 31.74 2,220.88 43.26 (
Slide 37: Contact
Contact Suven Life Sciences Ltd 6/F, Serene Chambers Road No. 5, Avenue 7 Banjara Hills Hyderabad 500034 Tel: +91 40 2354 1142 Fax: +91 40 2354 1152 [email protected] [email protected] In search of new CNS therapies for better living 37
Suven Life Sciences — Investor Presentation (March 2016) on 6ix